Fortress Biotech (FBIO)
(Delayed Data from NSDQ)
$1.75 USD
-0.05 (-2.78%)
Updated May 3, 2024 04:00 PM ET
After-Market: $1.75 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Fortress Biotech, Inc. [FBIO]
Reports for Purchase
Showing records 21 - 40 ( 312 total )
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Fortress: $76M in Revenues $181M in Cash
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Fortress is Down but Fundamentals Are Strong
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Updated Model - Challenging Environment, but Deep Value
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Avenue (ATXI-Not Rated), A ~20% Owned Fortress Company Raises $12M
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; Portfolio of Partnered Assets Continues to Build Momentum; Key Regulatory Filings on the Horizon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: NIAID grant for up to $20M to fund trial of Triplex CMV vaccine
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Reports First Quarter Results - $24M in Revenues, $290M in Consolidated Cash
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; Business Strategy Gathers Momentum; Numerous Regulatory Inflection Points Expected in 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
2021 Results; Hitting Real Strides With Cash Flow and Clinical Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J